<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01342926</url>
  </required_header>
  <id_info>
    <org_study_id>114341</org_study_id>
    <nct_id>NCT01342926</nct_id>
  </id_info>
  <brief_title>Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration</brief_title>
  <official_title>A Phase 2, Multi-centre, Randomised, Double-masked, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of GSK933776 in Adult Patients With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of GSK933776 in the
      treatment of geographic atrophy secondary to age-related macular degeneration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2a proof of concept study designed to evaluate the safety and efficacy of
      GSK933776 for the treatment of geographic atrophy secondary to age-related macular
      degeneration. This is a placebo-controlled parallel-group study that is double masked.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1, 2011</start_date>
  <completion_date type="Actual">April 1, 2016</completion_date>
  <primary_completion_date type="Actual">April 1, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in the Area of Geographic Atrophy (GA) Assessed by Color Fundus Photographs (FP) in the Study Eye</measure>
    <time_frame>Baseline (BL), 6 months, 12 months and 18 months</time_frame>
    <description>Atrophic age-related macular degeneration (AMD) also called GA is characterized by thinning of the retinal pigment epithelium (RPE) and underlying choriocapillaris, as well as overlying photoreceptors in the macula. GA was evaluated by color FP at the indicated time points: screening, 6 months, 12 months and 18 months. Change from BL: (screening, month 6, 12 or 18 value minus BL value. Note screening occurs prior to BL). Only participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Efficacy Population: all participants in the Intent-to-Treat (ITT) Population who met the protocol defined inclusion criterion for area of GA assessed by color FP in the study eye in at least one visit from screening visit through BL visit, inclusive and had data of area of GA assessed by fundus autofluorescence images in the study eye for at least 75% of the visits (&gt;=14 visits) from post-BL treatment month 2 visit to treatment month 19 visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Ocular or Non-ocular Adverse Events (AEs) During the Treatment Period</measure>
    <time_frame>Up to 21 months</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. It includes:1. Any abnormal laboratory test results or other safety assessments including those that worsen from Baseline, and felt to be clinically significant in the medical and scientific judgment of the Investigator 2.Exacerbation (increase in frequency/intensity) of a chronic or intermittent pre-existing condition 3. New conditions detected or diagnosed after screening visit 4. Signs, symptoms, or the clinical sequelae of a suspected interaction/suspected overdose of investigational product or a concomitant medication. AEs were presented as non-ocular and ocular AEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Ocular or Non-ocular Serious Adverse Events (SAEs) During the Treatment Period</measure>
    <time_frame>Up to 21 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Vital Signs of Potential Clinical Importance (PCI) During the Treatment Period: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)</measure>
    <time_frame>Up to 21 months</time_frame>
    <description>Vital signs included SBP and DBP of Potential Clinical Importance (PCI) at the indicated time points: Baseline, month 0, month 1, month 2, month 3, month 4, month 5, month 6, month 7, month 8, month 9, month 10, month 11, month 12, month 13, month 14, month 15, month 16, month 17, month 18, early withdrawal and at follow-up visit in sitting position. 'General' is an assessment time not relative to dosing. SBP was defined as: low: &lt;85 millimeter of mercury (mmHg) and high: &gt;160 mmHg and DBP was defined as: low:&lt;45 mmHg and high: &gt;100 mmHg. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Only categories with at least one PCI value are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Vital Signs of Potential Clinical Importance (PCI) During the Treatment Period: Heart Rate (HR)</measure>
    <time_frame>Baseline, Month 0, Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 7, Month 8, Month 9, Month 10, Month 11, Month 12, Month 13, Month 14, Month 15, Month 16, Month 17, Month 18, early withdrawal and at follow-up visit</time_frame>
    <description>Vital signs included HR of CCR at the indicated time points: Baseline, Month 0, Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 7, Month 8, Month 9, Month 10, Month 11, Month 12, Month 13, Month 14, Month 15, Month 16, Month 17, Month 18, early withdrawal and at follow-up visit in sitting position. 'General' is an assessment time not relative to dosing. HR was defined as: low:&lt; 40 beats per minute (bpm) and high: &gt;100 bpm. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Only categories with at least one PCI value are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With 12-lead Electrocardiogram (ECG) of Potential Clinical Importance (PCI)</measure>
    <time_frame>Baseline, Month 6, Month 12, Month 18, early withdrawal and at follow-up visit</time_frame>
    <description>12-lead ECG was obtained after 10 minutes rest in a supine position using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QT interval corrected using the Fridericia's formula (QTcF). Abnormal-clinically significant (CS) ECG measurements are presented at indicated time points: Baseline, Month 6, Month 12, Month 18, early withdrawal and at follow-up visit. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Laboratory Parameter Values of Potential Clinical Importance (PCI)</measure>
    <time_frame>At any point from Baseline through follow-up visit.</time_frame>
    <description>The following laboratory parameters were assessed: Hematology: Platelet Count, Red Blood Cell Count, White Blood Cell (WBC) Count, Reticulocyte Count, Hemoglobin, Hematocrit, Prothrombin time-International Normalized Ratio, Activated partial thromboplastin time, Mean corpuscular volume, Mean corpuscular haemoglobin, Mean corpuscular hemoglobin concentration, Neutrophils (ANC), Lymphocytes, Monocytes, Eosinophils, and Basophils. Clinical chemistry: Blood urea nitrogen, Potassium, Aspartate aminotransferase, Total and direct bilirubin Creatinine, Chloride, Alanine aminotransferase, Uric Acid, Glucose (fasting), Total Carbon dioxide , Gamma glutamyltransferase, Albumin, Sodium, Calcium, Alkaline phosphatase, Total Protein, and HbA1c. Urine: Specific gravity, pH, glucose, protein, blood and ketones and Microscopic examination. Only those with PCIs are displayed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>Month 2, Month 3, Month 4, Month 6, Month 12, Month 18 and at early withdrawal</time_frame>
    <description>Magnetic Resonance Imaging (MRI) was used as a safety assessment to monitor for amyloid related imaging abnormalities (ARIA) events in the brain. MRIs were performed at Baseline and before dose 2, before dose 3, before dose 4, before dose 6, before dose 12, before dose 18 and at follow-up. ARIA-edema/effusions (ARIA-E) and ARIA hemosiderin deposition (ARIA-H) events at any visit are reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Area of GA Assessed by Fundus Autofluorescence Images (hypoAF) Corresponding to GA in Study Eye</measure>
    <time_frame>Baseline, 6 months, 12 months and 18 months</time_frame>
    <description>Atrophic AMD also called as GA is characterized by thinning of the retinal pigment epithelium (RPE) and underlying choriocapillaris, as well as overlying photoreceptors in the macula. GA was evaluated by fundus autofluorescence images in the study eye at the indicated time points: screening, 6 months, 12 months and at 18 months. Change from Baseline: (months 6, 12,18 value minus Baseline value, respectively. Note screening occurs before baseline). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Area of Total hypoAF in Study Eye</measure>
    <time_frame>Baseline, 6 months, 12 months and 18 months</time_frame>
    <description>Atrophic AMD also called as GA is characterized by thinning of the retinal pigment epithelium (RPE) and underlying choriocapillaris, as well as overlying photoreceptors in the macula. GA was evaluated by fundus autofluorescence at the indicated time points: screening, 6 months, 12 months and at 18 months. Change from Baseline: (Month 6, 12, 18 value minus Baseline value, respectively. Note screening occurs before baseline). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Losing Letters in Early Treatment Diabetic Retinopathy Study (ETDRS)-Best Corrected Visual Acuity (BCVA) Score at Month 12 and Month 18 for Each Eye</measure>
    <time_frame>Month 12 and Month 18</time_frame>
    <description>Participants enrolled into the study were required to have a best-corrected ETDRS visual acuity score of at least 35 letters as determined by ETDRS-BCVA evaluation. ETDRS-BCVA score was assessed at the indiated time points at: Month 12 and Month 18 with categorical changes in the number of participants losing &gt;30, &gt;=15, &gt;=10, &gt;=5 and &lt;5 letters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in ETDRS-BCVA Score From Baseline at Every Month up to Month 18</measure>
    <time_frame>Baseline and every month up to Month 18</time_frame>
    <description>Participants enrolled into the study were required to have a best-corrected ETDRS visual acuity score of at least 35 letters as determined by ETDRS-BCVA evaluation. ETDRS-BCVA score was assessed as change from baseline in the mean best-corrected ETDRS visual acuity score at 18 months. Change from Baseline is defined as post-dose visit value minus Baseline value. Note that screening occurs before baseline. Values were truncated to one decimal place and negative sign retained where value is negative and the truncated value is zero. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time 0 to the End of Dosing Interval at Steady-state (AUC0-28d) of GSK933776 in Geographic Atrophy Participants</measure>
    <time_frame>Day 56, Day 63, 70 or 77, Day 84, Day 112, Day 140, Day 224, Day 308, Day 392 and Day 476</time_frame>
    <description>Area under the plasma concentration-time curve from time 0 to the end of dosing interval at steady-state; derived from dose and clearance parameters was evaluated. Blood samples were collected at the indicated time points on Day 56, Day 63, 70 or 77, Day 84, Day 112, Day 140, Day 224, Day 308, Day 392 and Day 476.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) and Pre-dose (Trough) Concentration at the End of the Dosing Interval (Ctau) of GSK933776 in Geographic Atrophy Participants</measure>
    <time_frame>Day 56, Day 63, 70 or 77, Day 84, Day 112, Day 140, Day 224, Day 308, Day 392 and Day 476</time_frame>
    <description>Blood samples were collected at the indicated time points on Day 56, Day 63, 70 or 77, Day 84, Day 112, Day 140, Day 224, Day 308, Day 392 and Day 476</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of GSK933776 in Geographic Atrophy Participants</measure>
    <time_frame>Day 56, Day 63, 70 or 77, Day 84, Day 112, Day 140, Day 224, Day 308, Day 392 and Day 476</time_frame>
    <description>Blood samples were collected at the indicated time points on Day 56, Day 63, 70 or 77, Day 84, Day 112, Day 140, Day 224, Day 308, Day 392 and Day 476.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimation of Terminal Phase Half-life (T1/2) of GSK933776 in Geographic Atrophy Participants</measure>
    <time_frame>Day 56, Day 63, 70 or 77, Day 84, Day 112, Day 140, Day 224, Day 308, Day 392 and Day 476</time_frame>
    <description>Blood samples were collected at the indicated time points on Day 56, Day 63, 70 or 77, Day 84, Day 112, Day 140, Day 224, Day 308, Day 392 and Day 476.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady-state (Vdss) of GSK933776 in Geographic Atrophy Participants Estimated From Population PK Modeling</measure>
    <time_frame>Day 56, Day 63, 70 or 77, Day 84, Day 112, Day 140, Day 224, Day 308, Day 392 and Day 476</time_frame>
    <description>Blood samples were collected at the indicated time points on Day 56, Day 63, 70 or 77, Day 84, Day 112, Day 140, Day 224, Day 308, Day 392 and Day 476.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Pharmacodynamic Effects of GSK933776 Total (Bound and Unbound) Plasma Total Amyloid Beta (Abeta42), and Amyloid Beta Fragments (Abeta18-35), if Possible, Unbound Plasma Aβ Fragments (Abeta1-22)</measure>
    <time_frame>Baseline, Month 3, Month 4, Month 5, Month 6, Month 9, Month 12, Month 15 and Month 18</time_frame>
    <description>Blood samples were collected at the indicated time points on Baseline, Month 3, Month 4, Month 5, Month 6, Month 9, Month 12, Month 15 and Month 18. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">191</enrollment>
  <condition>Atrophy, Geographic</condition>
  <arm_group>
    <arm_group_label>GSK933776 3 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 mg/kg administration of GSK933776 via intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK933776 6 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 mg/kg administration of GSK933776 via intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo via intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK933776 15 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg/kg administration of GSK933776 via intravenous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK933776</intervention_name>
    <description>GSK933776</description>
    <arm_group_label>GSK933776 3 mg/kg</arm_group_label>
    <arm_group_label>GSK933776 15 mg/kg</arm_group_label>
    <arm_group_label>GSK933776 6 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients ≥55 years of age inclusive

          -  Evidence of AMD confirmed by the presence of at least 1 druse ≥125 μm diameter

          -  Well-demarcated GA due to AMD of total area 1.9-17 mm2 measured in the study eye

          -  Best-corrected visual acuity score of ≥ 35 letters (approximately 20/200 Snellen VA
             equivalent or better) in the study eye

        Exclusion Criteria:

          -  Additional eye disease in the study eye that could compromise assessment of
             best-corrected visual acuity or imaging of the posterior pole

          -  History of CNV secondary to AMD in the study eye

          -  Any previous treatment for AMD in the study eye, approved or investigational, with the
             exception of dietary supplements

          -  Risk of cerebrovascular disease, cerebral hemorrhage or stroke

          -  History of systemic autoimmune disease

          -  Use of platelet anti-aggregants or anti-coagulants (aspirin up to 325 mg/day is
             allowable, or in subjects allergic or intolerable to aspirin, clopidogrel up to 75
             mg/day is allowable)

          -  Use of chronic corticosteroids

          -  Uncontrolled hypertension in spite of antihypertensive medications

          -  Renal or hepatic insufficiency or clinically significant anemia

          -  More than moderate MRI white matter changes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033-4500</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stuart</city>
        <state>Florida</state>
        <zip>34994</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leawood</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Prairie Village</city>
        <state>Kansas</state>
        <zip>66208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Northfield</city>
        <state>New Jersey</state>
        <zip>08225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>West Mifflin</city>
        <state>Pennsylvania</state>
        <zip>15122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ladson</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Abilene</city>
        <state>Texas</state>
        <zip>79606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Silverdale</city>
        <state>Washington</state>
        <zip>98383</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L4W 1W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2011</study_first_submitted>
  <study_first_submitted_qc>April 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2011</study_first_posted>
  <results_first_submitted>November 30, 2016</results_first_submitted>
  <results_first_submitted_qc>March 27, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 5, 2017</results_first_posted>
  <last_update_submitted>March 27, 2017</last_update_submitted>
  <last_update_submitted_qc>March 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>age-related macular degeneration</keyword>
  <keyword>geographic atrophy</keyword>
  <keyword>dry AMD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Geographic Atrophy</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was a parallel-group randomized study consisted of a screening visit, where 240 participants entered the observation period (minimum of 4 months), a Baseline visit at the end of observation phase, where 191 were randomized, and was followed by the treatment period (18 months), and a follow-up visit (3 months) after last dose.</recruitment_details>
      <pre_assignment_details>The total duration of participation was approximately 25 months following screening.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received placebo (0.9 percent sodium chloride) by intravenous (IV) infusion every 28 days for 18 months.</description>
        </group>
        <group group_id="P2">
          <title>GSK933776 (3 mg/kg)</title>
          <description>Participants received 3 milligram (mg)/kilogram (kg) GSK933776 by IV infusion every 28 days for 18 months.</description>
        </group>
        <group group_id="P3">
          <title>GSK933776 (6 mg/kg)</title>
          <description>Participants received 6 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
        </group>
        <group group_id="P4">
          <title>GSK933776 (15 mg/kg)</title>
          <description>Participants received 15 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="48"/>
                <participants group_id="P4" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="34"/>
                <participants group_id="P4" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator Discretion</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo via intravenous infusion</description>
        </group>
        <group group_id="B2">
          <title>GSK933776 3 mg/kg</title>
          <description>3 mg/kg administration of GSK933776 via intravenous infusion</description>
        </group>
        <group group_id="B3">
          <title>GSK933776 6 mg/kg</title>
          <description>6 mg/kg administration of GSK933776 via intravenous infusion</description>
        </group>
        <group group_id="B4">
          <title>GSK933776 15 mg/kg</title>
          <description>15 mg/kg administration of GSK933776 via intravenous infusion</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
            <count group_id="B2" value="46"/>
            <count group_id="B3" value="48"/>
            <count group_id="B4" value="51"/>
            <count group_id="B5" value="191"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.3" spread="9.55"/>
                    <measurement group_id="B2" value="77.2" spread="9.09"/>
                    <measurement group_id="B3" value="77.5" spread="8.57"/>
                    <measurement group_id="B4" value="78.6" spread="7.22"/>
                    <measurement group_id="B5" value="77.2" spread="8.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="109"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African American/African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the Area of Geographic Atrophy (GA) Assessed by Color Fundus Photographs (FP) in the Study Eye</title>
        <description>Atrophic age-related macular degeneration (AMD) also called GA is characterized by thinning of the retinal pigment epithelium (RPE) and underlying choriocapillaris, as well as overlying photoreceptors in the macula. GA was evaluated by color FP at the indicated time points: screening, 6 months, 12 months and 18 months. Change from BL: (screening, month 6, 12 or 18 value minus BL value. Note screening occurs prior to BL). Only participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Efficacy Population: all participants in the Intent-to-Treat (ITT) Population who met the protocol defined inclusion criterion for area of GA assessed by color FP in the study eye in at least one visit from screening visit through BL visit, inclusive and had data of area of GA assessed by fundus autofluorescence images in the study eye for at least 75% of the visits (&gt;=14 visits) from post-BL treatment month 2 visit to treatment month 19 visit.</description>
        <time_frame>Baseline (BL), 6 months, 12 months and 18 months</time_frame>
        <population>Efficacy Population. Participants who developed CNV in the study eye during the treatment period are excluded from Efficacy Population per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo (0.9 percent sodium chloride) by intravenous (IV) infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O2">
            <title>GSK933776 (3 mg/kg)</title>
            <description>Participants received 3 milligram (mg)/kilogram (kg) GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O3">
            <title>GSK933776 (6 mg/kg)</title>
            <description>Participants received 6 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O4">
            <title>GSK933776 (15 mg/kg)</title>
            <description>Participants received 15 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Area of Geographic Atrophy (GA) Assessed by Color Fundus Photographs (FP) in the Study Eye</title>
          <description>Atrophic age-related macular degeneration (AMD) also called GA is characterized by thinning of the retinal pigment epithelium (RPE) and underlying choriocapillaris, as well as overlying photoreceptors in the macula. GA was evaluated by color FP at the indicated time points: screening, 6 months, 12 months and 18 months. Change from BL: (screening, month 6, 12 or 18 value minus BL value. Note screening occurs prior to BL). Only participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Efficacy Population: all participants in the Intent-to-Treat (ITT) Population who met the protocol defined inclusion criterion for area of GA assessed by color FP in the study eye in at least one visit from screening visit through BL visit, inclusive and had data of area of GA assessed by fundus autofluorescence images in the study eye for at least 75% of the visits (&gt;=14 visits) from post-BL treatment month 2 visit to treatment month 19 visit.</description>
          <population>Efficacy Population. Participants who developed CNV in the study eye during the treatment period are excluded from Efficacy Population per protocol.</population>
          <units>square millimeter (m^2)</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening, n=34, 30, 35, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" lower_limit="-0.86" upper_limit="-0.17"/>
                    <measurement group_id="O2" value="-0.94" lower_limit="-1.30" upper_limit="-0.57"/>
                    <measurement group_id="O3" value="-0.99" lower_limit="-1.33" upper_limit="-0.65"/>
                    <measurement group_id="O4" value="-0.96" lower_limit="-1.28" upper_limit="-0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months, n=34, 30, 35, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" lower_limit="0.61" upper_limit="1.30"/>
                    <measurement group_id="O2" value="0.88" lower_limit="0.51" upper_limit="1.25"/>
                    <measurement group_id="O3" value="0.73" lower_limit="0.38" upper_limit="1.07"/>
                    <measurement group_id="O4" value="0.77" lower_limit="0.44" upper_limit="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months, n=33, 29, 34, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" lower_limit="1.26" upper_limit="1.95"/>
                    <measurement group_id="O2" value="1.81" lower_limit="1.43" upper_limit="2.18"/>
                    <measurement group_id="O3" value="1.83" lower_limit="1.49" upper_limit="2.18"/>
                    <measurement group_id="O4" value="1.89" lower_limit="1.57" upper_limit="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 months, n=34, 30, 32, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.60" lower_limit="2.25" upper_limit="2.95"/>
                    <measurement group_id="O2" value="2.77" lower_limit="2.40" upper_limit="3.14"/>
                    <measurement group_id="O3" value="2.88" lower_limit="2.53" upper_limit="3.23"/>
                    <measurement group_id="O4" value="2.99" lower_limit="2.67" upper_limit="3.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.07</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.57</ci_lower_limit>
            <ci_upper_limit>0.43</ci_upper_limit>
            <estimate_desc>6 months visit</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.20</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.31</ci_lower_limit>
            <ci_upper_limit>0.71</ci_upper_limit>
            <estimate_desc>12 months visit</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.17</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.33</ci_lower_limit>
            <ci_upper_limit>0.68</ci_upper_limit>
            <estimate_desc>18 months visit</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.23</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.71</ci_lower_limit>
            <ci_upper_limit>0.26</ci_upper_limit>
            <estimate_desc>6 months visit</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.23</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.26</ci_lower_limit>
            <ci_upper_limit>0.72</ci_upper_limit>
            <estimate_desc>12 months visit</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.28</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.21</ci_lower_limit>
            <ci_upper_limit>0.77</ci_upper_limit>
            <estimate_desc>18 months visit</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.18</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.66</ci_lower_limit>
            <ci_upper_limit>0.29</ci_upper_limit>
            <estimate_desc>6 months visit</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.28</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.19</ci_lower_limit>
            <ci_upper_limit>0.75</ci_upper_limit>
            <estimate_desc>12 months visit</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.39</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.08</ci_lower_limit>
            <ci_upper_limit>0.86</ci_upper_limit>
            <estimate_desc>18 months visit</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Ocular or Non-ocular Adverse Events (AEs) During the Treatment Period</title>
        <description>An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. It includes:1. Any abnormal laboratory test results or other safety assessments including those that worsen from Baseline, and felt to be clinically significant in the medical and scientific judgment of the Investigator 2.Exacerbation (increase in frequency/intensity) of a chronic or intermittent pre-existing condition 3. New conditions detected or diagnosed after screening visit 4. Signs, symptoms, or the clinical sequelae of a suspected interaction/suspected overdose of investigational product or a concomitant medication. AEs were presented as non-ocular and ocular AEs.</description>
        <time_frame>Up to 21 months</time_frame>
        <population>ITT Population: all participants that completed the observation period and Baseline visit, and were subsequently randomized to treatment and were administered at least one IV dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo (0.9 percent sodium chloride) by intravenous (IV) infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O2">
            <title>GSK933776 (3 mg/kg)</title>
            <description>Participants received 3 milligram (mg)/kilogram (kg) GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O3">
            <title>GSK933776 (6 mg/kg)</title>
            <description>Participants received 6 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O4">
            <title>GSK933776 (15 mg/kg)</title>
            <description>Participants received 15 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ocular or Non-ocular Adverse Events (AEs) During the Treatment Period</title>
          <description>An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. It includes:1. Any abnormal laboratory test results or other safety assessments including those that worsen from Baseline, and felt to be clinically significant in the medical and scientific judgment of the Investigator 2.Exacerbation (increase in frequency/intensity) of a chronic or intermittent pre-existing condition 3. New conditions detected or diagnosed after screening visit 4. Signs, symptoms, or the clinical sequelae of a suspected interaction/suspected overdose of investigational product or a concomitant medication. AEs were presented as non-ocular and ocular AEs.</description>
          <population>ITT Population: all participants that completed the observation period and Baseline visit, and were subsequently randomized to treatment and were administered at least one IV dose.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-ocular AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="44"/>
                    <measurement group_id="O4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ocular AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Ocular or Non-ocular Serious Adverse Events (SAEs) During the Treatment Period</title>
        <time_frame>Up to 21 months</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo (0.9 percent sodium chloride) by intravenous (IV) infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O2">
            <title>GSK933776 (3 mg/kg)</title>
            <description>Participants received 3 milligram (mg)/kilogram (kg) GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O3">
            <title>GSK933776 (6 mg/kg)</title>
            <description>Participants received 6 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O4">
            <title>GSK933776 (15 mg/kg)</title>
            <description>Participants received 15 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ocular or Non-ocular Serious Adverse Events (SAEs) During the Treatment Period</title>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-ocular SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ocular SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Vital Signs of Potential Clinical Importance (PCI) During the Treatment Period: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)</title>
        <description>Vital signs included SBP and DBP of Potential Clinical Importance (PCI) at the indicated time points: Baseline, month 0, month 1, month 2, month 3, month 4, month 5, month 6, month 7, month 8, month 9, month 10, month 11, month 12, month 13, month 14, month 15, month 16, month 17, month 18, early withdrawal and at follow-up visit in sitting position. 'General' is an assessment time not relative to dosing. SBP was defined as: low: &lt;85 millimeter of mercury (mmHg) and high: &gt;160 mmHg and DBP was defined as: low:&lt;45 mmHg and high: &gt;100 mmHg. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Only categories with at least one PCI value are presented.</description>
        <time_frame>Up to 21 months</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo (0.9 percent sodium chloride) by intravenous (IV) infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O2">
            <title>GSK933776 (3 mg/kg)</title>
            <description>Participants received 3 milligram (mg)/kilogram (kg) GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O3">
            <title>GSK933776 (6 mg/kg)</title>
            <description>Participants received 6 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O4">
            <title>GSK933776 (15 mg/kg)</title>
            <description>Participants received 15 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vital Signs of Potential Clinical Importance (PCI) During the Treatment Period: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)</title>
          <description>Vital signs included SBP and DBP of Potential Clinical Importance (PCI) at the indicated time points: Baseline, month 0, month 1, month 2, month 3, month 4, month 5, month 6, month 7, month 8, month 9, month 10, month 11, month 12, month 13, month 14, month 15, month 16, month 17, month 18, early withdrawal and at follow-up visit in sitting position. 'General' is an assessment time not relative to dosing. SBP was defined as: low: &lt;85 millimeter of mercury (mmHg) and high: &gt;160 mmHg and DBP was defined as: low:&lt;45 mmHg and high: &gt;100 mmHg. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Only categories with at least one PCI value are presented.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP Baseline General: &gt; CCR, n=46, 46, 48, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Baseline General 2:&gt; CCR, n=46, 46, 48, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Baseline General 3:&gt; CCR, n=45, 46, 48, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 0, Pre-dose:&gt; CCR, n=46, 46, 48, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 0, 0 H:&gt; CCR, n=46, 46, 48, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 1, Pre-dose:&gt; CCR, n=44, 44, 44, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 1, 0 H:&gt; CCR, n=43, 44, 44, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 2, Pre-dose:&gt; CCR, n=44, 43, 42, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 2, 0 H:&gt; CCR, n=44, 41, 41, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 3, Pre-dose:&gt; CCR, n=44, 37, 42, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 3, 0 H:&gt; CCR, n=42, 35, 40, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 4, Pre-dose:&gt; CCR, n=43, 36, 42, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 4, 0 H:&gt; CCR, n=43, 34, 42, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 5, Pre-dose:&gt; CCR, n=43, 36, 40, 45</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 5, 0 H:&gt; CCR, n=42, 36, 39, 45</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 6, Pre-dose:&gt; CCR, n=43, 36, 40, 45</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 6, 0 H:&gt; CCR, n=42, 36, 40, 45</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 7, Pre-dose:&gt; CCR, n=43, 35, 40, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 7, 0 H:&gt; CCR, n=43, 33, 40, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 8, Pre-dose:&gt; CCR, n=42, 33, 40, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 8, 0 H:&gt; CCR, n=41, 33, 40, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 9, Pre-dose:&gt; CCR, n=41, 33, 40, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 9, Pre-dose:&lt; CCR, n=41, 33, 40, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 9, 0 H:&gt; CCR, n=41, 33, 39, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 10, Pre-dose:&gt; CCR, n=41, 32, 40, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 10, 0 H:&gt; CCR, n=40, 32, 40, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 11, Pre-dose:&gt; CCR, n=41, 33, 39, 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 11, 0 H:&gt; CCR, n=40, 31, 35, 41</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 11, 0 H:&lt; CCR, n=40, 31, 35, 41</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 12, Pre-dose:&gt; CCR, n=39, 30, 38, 41</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 12, 0 H:&gt; CCR, n=39, 30, 38, 41</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 13, Pre-dose:&gt; CCR, n=38, 31, 39, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 13, 0 H:&gt; CCR, n=38, 31, 39, 38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 14, Pre-dose:&gt; CCR, n=38, 31, 36, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 14, 0 H:&gt; CCR, n=38, 31, 36, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 15, Pre-dose:&gt; CCR, n=37, 31, 35, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 15, 0 H:&gt; CCR, n=37, 31, 35, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 16, Pre-dose:&gt; CCR, n=37, 31, 35, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 16, 0 H:&gt; CCR, n=37, 31, 35, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 17, Pre-dose:&gt; CCR, n=38, 32, 36, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 17, 0 H:&gt; CCR, n=37, 30, 34, 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 17, 0 H:&lt; CCR, n=37, 30, 34, 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Month 18, General:&gt; CCR, n=36, 31, 33, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Early withdrawal, :&gt; CCR, n=8, 8, 7, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Follow-up:&gt; CCR, n=39, 36, 37, 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP Month 4, 0 H:&lt; CCR, n=43, 34, 42, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP Month 8, 0 H:&gt; CCR, n=41, 33, 40, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP Month 9, Pre-dose:&gt; CCR, n=41, 33, 40, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP Month 11, Pre-dose:&gt; CCR, n=41, 33, 39, 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP Month 13, Pre-dose:&lt; CCR, n=38, 31, 39, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Vital Signs of Potential Clinical Importance (PCI) During the Treatment Period: Heart Rate (HR)</title>
        <description>Vital signs included HR of CCR at the indicated time points: Baseline, Month 0, Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 7, Month 8, Month 9, Month 10, Month 11, Month 12, Month 13, Month 14, Month 15, Month 16, Month 17, Month 18, early withdrawal and at follow-up visit in sitting position. 'General' is an assessment time not relative to dosing. HR was defined as: low:&lt; 40 beats per minute (bpm) and high: &gt;100 bpm. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Only categories with at least one PCI value are presented.</description>
        <time_frame>Baseline, Month 0, Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 7, Month 8, Month 9, Month 10, Month 11, Month 12, Month 13, Month 14, Month 15, Month 16, Month 17, Month 18, early withdrawal and at follow-up visit</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo (0.9 percent sodium chloride) by intravenous (IV) infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O2">
            <title>GSK933776 (3 mg/kg)</title>
            <description>Participants received 3 milligram (mg)/kilogram (kg) GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O3">
            <title>GSK933776 (6 mg/kg)</title>
            <description>Participants received 6 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O4">
            <title>GSK933776 (15 mg/kg)</title>
            <description>Participants received 15 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vital Signs of Potential Clinical Importance (PCI) During the Treatment Period: Heart Rate (HR)</title>
          <description>Vital signs included HR of CCR at the indicated time points: Baseline, Month 0, Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 7, Month 8, Month 9, Month 10, Month 11, Month 12, Month 13, Month 14, Month 15, Month 16, Month 17, Month 18, early withdrawal and at follow-up visit in sitting position. 'General' is an assessment time not relative to dosing. HR was defined as: low:&lt; 40 beats per minute (bpm) and high: &gt;100 bpm. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Only categories with at least one PCI value are presented.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HR Month 3, Pre-dose:&gt; CCR, n=44, 37, 42, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR Month 13, Pre-dose:&gt; CCR, n=38, 31, 39, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With 12-lead Electrocardiogram (ECG) of Potential Clinical Importance (PCI)</title>
        <description>12-lead ECG was obtained after 10 minutes rest in a supine position using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QT interval corrected using the Fridericia's formula (QTcF). Abnormal-clinically significant (CS) ECG measurements are presented at indicated time points: Baseline, Month 6, Month 12, Month 18, early withdrawal and at follow-up visit. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
        <time_frame>Baseline, Month 6, Month 12, Month 18, early withdrawal and at follow-up visit</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo (0.9 percent sodium chloride) by intravenous (IV) infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O2">
            <title>GSK933776 (3 mg/kg)</title>
            <description>Participants received 3 milligram (mg)/kilogram (kg) GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O3">
            <title>GSK933776 (6 mg/kg)</title>
            <description>Participants received 6 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O4">
            <title>GSK933776 (15 mg/kg)</title>
            <description>Participants received 15 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With 12-lead Electrocardiogram (ECG) of Potential Clinical Importance (PCI)</title>
          <description>12-lead ECG was obtained after 10 minutes rest in a supine position using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QT interval corrected using the Fridericia's formula (QTcF). Abnormal-clinically significant (CS) ECG measurements are presented at indicated time points: Baseline, Month 6, Month 12, Month 18, early withdrawal and at follow-up visit. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ECG:CS Baseline, n=46, 46, 48, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECG:CS Month 6, n=41, 33, 37, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECG:CS Month 12, n=41, 32, 40, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECG:CS Month 18, n=38, 30, 36, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECG:CS early withdrawal, n=7, 8, 7, 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECG:CS follow-up, n=39, 37, 37, 38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Laboratory Parameter Values of Potential Clinical Importance (PCI)</title>
        <description>The following laboratory parameters were assessed: Hematology: Platelet Count, Red Blood Cell Count, White Blood Cell (WBC) Count, Reticulocyte Count, Hemoglobin, Hematocrit, Prothrombin time-International Normalized Ratio, Activated partial thromboplastin time, Mean corpuscular volume, Mean corpuscular haemoglobin, Mean corpuscular hemoglobin concentration, Neutrophils (ANC), Lymphocytes, Monocytes, Eosinophils, and Basophils. Clinical chemistry: Blood urea nitrogen, Potassium, Aspartate aminotransferase, Total and direct bilirubin Creatinine, Chloride, Alanine aminotransferase, Uric Acid, Glucose (fasting), Total Carbon dioxide , Gamma glutamyltransferase, Albumin, Sodium, Calcium, Alkaline phosphatase, Total Protein, and HbA1c. Urine: Specific gravity, pH, glucose, protein, blood and ketones and Microscopic examination. Only those with PCIs are displayed.</description>
        <time_frame>At any point from Baseline through follow-up visit.</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo (0.9 percent sodium chloride) by intravenous (IV) infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O2">
            <title>GSK933776 (3 mg/kg)</title>
            <description>Participants received 3 milligram (mg)/kilogram (kg) GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O3">
            <title>GSK933776 (6 mg/kg)</title>
            <description>Participants received 6 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O4">
            <title>GSK933776 (15 mg/kg)</title>
            <description>Participants received 15 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Laboratory Parameter Values of Potential Clinical Importance (PCI)</title>
          <description>The following laboratory parameters were assessed: Hematology: Platelet Count, Red Blood Cell Count, White Blood Cell (WBC) Count, Reticulocyte Count, Hemoglobin, Hematocrit, Prothrombin time-International Normalized Ratio, Activated partial thromboplastin time, Mean corpuscular volume, Mean corpuscular haemoglobin, Mean corpuscular hemoglobin concentration, Neutrophils (ANC), Lymphocytes, Monocytes, Eosinophils, and Basophils. Clinical chemistry: Blood urea nitrogen, Potassium, Aspartate aminotransferase, Total and direct bilirubin Creatinine, Chloride, Alanine aminotransferase, Uric Acid, Glucose (fasting), Total Carbon dioxide , Gamma glutamyltransferase, Albumin, Sodium, Calcium, Alkaline phosphatase, Total Protein, and HbA1c. Urine: Specific gravity, pH, glucose, protein, blood and ketones and Microscopic examination. Only those with PCIs are displayed.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alanine Amino Transferase (less than PCI low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Amino Transferase (Above PCI high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Amino Transferase (less than PCI low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Amino Transferase (Above PCI high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium (less than PCI low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium (Above PCI high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CO2 content/Bicarbonate (less than PCI low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CO2 content/B icarbonate (AbovePCI high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine (less than PCI low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine (Above PCI high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose (less than PCI low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose (Above PCI high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium (less than PCI low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium (Above PCI high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium (Less than PCI low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium (Above the PCI high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin (less than PCI low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin (Above the PCI high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit (less than PCI low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit (Above PCI high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (less than PCI low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (Above PCI high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total ANC (less than PCI low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total ANC (Above PCI high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count (less than PCI low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count (Above PCI high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC count (less than PCI low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC count (Above PCI high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Magnetic Resonance Imaging (MRI)</title>
        <description>Magnetic Resonance Imaging (MRI) was used as a safety assessment to monitor for amyloid related imaging abnormalities (ARIA) events in the brain. MRIs were performed at Baseline and before dose 2, before dose 3, before dose 4, before dose 6, before dose 12, before dose 18 and at follow-up. ARIA-edema/effusions (ARIA-E) and ARIA hemosiderin deposition (ARIA-H) events at any visit are reported.</description>
        <time_frame>Month 2, Month 3, Month 4, Month 6, Month 12, Month 18 and at early withdrawal</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo (0.9 percent sodium chloride) by intravenous (IV) infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O2">
            <title>GSK933776 (3 mg/kg)</title>
            <description>Participants received 3 milligram (mg)/kilogram (kg) GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O3">
            <title>GSK933776 (6 mg/kg)</title>
            <description>Participants received 6 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O4">
            <title>GSK933776 (15 mg/kg)</title>
            <description>Participants received 15 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Magnetic Resonance Imaging (MRI)</title>
          <description>Magnetic Resonance Imaging (MRI) was used as a safety assessment to monitor for amyloid related imaging abnormalities (ARIA) events in the brain. MRIs were performed at Baseline and before dose 2, before dose 3, before dose 4, before dose 6, before dose 12, before dose 18 and at follow-up. ARIA-edema/effusions (ARIA-E) and ARIA hemosiderin deposition (ARIA-H) events at any visit are reported.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ARIA E</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARIA H</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Area of GA Assessed by Fundus Autofluorescence Images (hypoAF) Corresponding to GA in Study Eye</title>
        <description>Atrophic AMD also called as GA is characterized by thinning of the retinal pigment epithelium (RPE) and underlying choriocapillaris, as well as overlying photoreceptors in the macula. GA was evaluated by fundus autofluorescence images in the study eye at the indicated time points: screening, 6 months, 12 months and at 18 months. Change from Baseline: (months 6, 12,18 value minus Baseline value, respectively. Note screening occurs before baseline). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
        <time_frame>Baseline, 6 months, 12 months and 18 months</time_frame>
        <population>Efficacy Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo (0.9 percent sodium chloride) by intravenous (IV) infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O2">
            <title>GSK933776 (3 mg/kg)</title>
            <description>Participants received 3 milligram (mg)/kilogram (kg) GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O3">
            <title>GSK933776 (6 mg/kg)</title>
            <description>Participants received 6 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O4">
            <title>GSK933776 (15 mg/kg)</title>
            <description>Participants received 15 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Area of GA Assessed by Fundus Autofluorescence Images (hypoAF) Corresponding to GA in Study Eye</title>
          <description>Atrophic AMD also called as GA is characterized by thinning of the retinal pigment epithelium (RPE) and underlying choriocapillaris, as well as overlying photoreceptors in the macula. GA was evaluated by fundus autofluorescence images in the study eye at the indicated time points: screening, 6 months, 12 months and at 18 months. Change from Baseline: (months 6, 12,18 value minus Baseline value, respectively. Note screening occurs before baseline). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
          <population>Efficacy Population</population>
          <units>mm^2</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening, n=33, 30, 34, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" lower_limit="-1.02" upper_limit="-0.37"/>
                    <measurement group_id="O2" value="-0.62" lower_limit="-0.97" upper_limit="-0.28"/>
                    <measurement group_id="O3" value="-0.74" lower_limit="-1.06" upper_limit="-0.42"/>
                    <measurement group_id="O4" value="-0.74" lower_limit="-1.03" upper_limit="-0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months, n=33, 30, 34, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" lower_limit="0.48" upper_limit="1.13"/>
                    <measurement group_id="O2" value="0.94" lower_limit="0.60" upper_limit="1.29"/>
                    <measurement group_id="O3" value="0.72" lower_limit="0.40" upper_limit="1.04"/>
                    <measurement group_id="O4" value="0.94" lower_limit="0.64" upper_limit="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months, n=32, 29, 33, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" lower_limit="1.00" upper_limit="1.67"/>
                    <measurement group_id="O2" value="1.74" lower_limit="1.39" upper_limit="2.09"/>
                    <measurement group_id="O3" value="1.67" lower_limit="1.34" upper_limit="1.99"/>
                    <measurement group_id="O4" value="1.87" lower_limit="1.58" upper_limit="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 months, n=33, 30, 31, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.24" lower_limit="1.91" upper_limit="2.57"/>
                    <measurement group_id="O2" value="2.65" lower_limit="2.31" upper_limit="3.00"/>
                    <measurement group_id="O3" value="2.41" lower_limit="2.08" upper_limit="2.73"/>
                    <measurement group_id="O4" value="3.15" lower_limit="2.85" upper_limit="3.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.14</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.34</ci_lower_limit>
            <ci_upper_limit>0.61</ci_upper_limit>
            <estimate_desc>6 months visit</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.41</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.07</ci_lower_limit>
            <ci_upper_limit>0.89</ci_upper_limit>
            <estimate_desc>12 months visit</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.42</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.06</ci_lower_limit>
            <ci_upper_limit>0.89</ci_upper_limit>
            <estimate_desc>18 months visit</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.09</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.55</ci_lower_limit>
            <ci_upper_limit>0.37</ci_upper_limit>
            <estimate_desc>6 months visit</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.33</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.13</ci_lower_limit>
            <ci_upper_limit>0.80</ci_upper_limit>
            <estimate_desc>12 months visit</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.17</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.30</ci_lower_limit>
            <ci_upper_limit>0.63</ci_upper_limit>
            <estimate_desc>18 months visit</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.13</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.31</ci_lower_limit>
            <ci_upper_limit>0.57</ci_upper_limit>
            <estimate_desc>6 months visit</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.54</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.10</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
            <estimate_desc>12 months visit</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.91</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>1.36</ci_upper_limit>
            <estimate_desc>18 months visit</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Area of Total hypoAF in Study Eye</title>
        <description>Atrophic AMD also called as GA is characterized by thinning of the retinal pigment epithelium (RPE) and underlying choriocapillaris, as well as overlying photoreceptors in the macula. GA was evaluated by fundus autofluorescence at the indicated time points: screening, 6 months, 12 months and at 18 months. Change from Baseline: (Month 6, 12, 18 value minus Baseline value, respectively. Note screening occurs before baseline). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
        <time_frame>Baseline, 6 months, 12 months and 18 months</time_frame>
        <population>Efficacy Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo (0.9 percent sodium chloride) by intravenous (IV) infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O2">
            <title>GSK933776 (3 mg/kg)</title>
            <description>Participants received 3 milligram (mg)/kilogram (kg) GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O3">
            <title>GSK933776 (6 mg/kg)</title>
            <description>Participants received 6 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O4">
            <title>GSK933776 (15 mg/kg)</title>
            <description>Participants received 15 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Area of Total hypoAF in Study Eye</title>
          <description>Atrophic AMD also called as GA is characterized by thinning of the retinal pigment epithelium (RPE) and underlying choriocapillaris, as well as overlying photoreceptors in the macula. GA was evaluated by fundus autofluorescence at the indicated time points: screening, 6 months, 12 months and at 18 months. Change from Baseline: (Month 6, 12, 18 value minus Baseline value, respectively. Note screening occurs before baseline). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
          <population>Efficacy Population</population>
          <units>mm^2</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening, n=33, 30, 34, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.65" lower_limit="-0.95" upper_limit="-0.34"/>
                    <measurement group_id="O2" value="-0.63" lower_limit="-0.95" upper_limit="0.31"/>
                    <measurement group_id="O3" value="-0.71" lower_limit="-1.01" upper_limit="-0.41"/>
                    <measurement group_id="O4" value="-1.20" lower_limit="-1.48" upper_limit="-0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months, n=33, 30, 34, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" lower_limit="0.60" upper_limit="1.21"/>
                    <measurement group_id="O2" value="1.01" lower_limit="0.69" upper_limit="1.33"/>
                    <measurement group_id="O3" value="0.83" lower_limit="0.53" upper_limit="1.13"/>
                    <measurement group_id="O4" value="0.84" lower_limit="0.56" upper_limit="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months, n=32, 29, 33, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.44" lower_limit="1.13" upper_limit="1.76"/>
                    <measurement group_id="O2" value="1.90" lower_limit="1.57" upper_limit="2.22"/>
                    <measurement group_id="O3" value="1.67" lower_limit="1.36" upper_limit="1.97"/>
                    <measurement group_id="O4" value="1.64" lower_limit="1.36" upper_limit="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 months, n=33, 30, 31, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.35" lower_limit="2.04" upper_limit="2.65"/>
                    <measurement group_id="O2" value="2.67" lower_limit="2.35" upper_limit="2.99"/>
                    <measurement group_id="O3" value="2.46" lower_limit="2.15" upper_limit="2.77"/>
                    <measurement group_id="O4" value="2.85" lower_limit="2.57" upper_limit="3.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.10</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.34</ci_lower_limit>
            <ci_upper_limit>0.55</ci_upper_limit>
            <estimate_desc>6 months visit</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.45</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.00</ci_lower_limit>
            <ci_upper_limit>0.90</ci_upper_limit>
            <estimate_desc>12 months visit</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.33</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.12</ci_lower_limit>
            <ci_upper_limit>0.77</ci_upper_limit>
            <estimate_desc>18 months visit</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.08</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.51</ci_lower_limit>
            <ci_upper_limit>0.35</ci_upper_limit>
            <estimate_desc>6 months visit</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.23</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.21</ci_lower_limit>
            <ci_upper_limit>0.66</ci_upper_limit>
            <estimate_desc>12 months visit</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.12</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.32</ci_lower_limit>
            <ci_upper_limit>0.55</ci_upper_limit>
            <estimate_desc>18 months visit</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.06</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>0.35</ci_upper_limit>
            <estimate_desc>6 months visit</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.20</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.22</ci_lower_limit>
            <ci_upper_limit>0.62</ci_upper_limit>
            <estimate_desc>12 months visit</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.50</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.08</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
            <estimate_desc>18 months visit</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Losing Letters in Early Treatment Diabetic Retinopathy Study (ETDRS)-Best Corrected Visual Acuity (BCVA) Score at Month 12 and Month 18 for Each Eye</title>
        <description>Participants enrolled into the study were required to have a best-corrected ETDRS visual acuity score of at least 35 letters as determined by ETDRS-BCVA evaluation. ETDRS-BCVA score was assessed at the indiated time points at: Month 12 and Month 18 with categorical changes in the number of participants losing &gt;30, &gt;=15, &gt;=10, &gt;=5 and &lt;5 letters.</description>
        <time_frame>Month 12 and Month 18</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo (0.9 percent sodium chloride) by intravenous (IV) infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O2">
            <title>GSK933776 (3 mg/kg)</title>
            <description>Participants received 3 milligram (mg)/kilogram (kg) GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O3">
            <title>GSK933776 (6 mg/kg)</title>
            <description>Participants received 6 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O4">
            <title>GSK933776 (15 mg/kg)</title>
            <description>Participants received 15 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Losing Letters in Early Treatment Diabetic Retinopathy Study (ETDRS)-Best Corrected Visual Acuity (BCVA) Score at Month 12 and Month 18 for Each Eye</title>
          <description>Participants enrolled into the study were required to have a best-corrected ETDRS visual acuity score of at least 35 letters as determined by ETDRS-BCVA evaluation. ETDRS-BCVA score was assessed at the indiated time points at: Month 12 and Month 18 with categorical changes in the number of participants losing &gt;30, &gt;=15, &gt;=10, &gt;=5 and &lt;5 letters.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>M12:Study eye, Losing &gt; 30 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12:Study eye, Losing &gt;= 15 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12:Study eye, Losing &gt;= 10 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12:Study eye, Losing &gt;= 5 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12:Study eye, Losing &lt;5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12:fellow eye, Losing &gt; 30 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12:fellow eye, Losing &gt;= 15 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12:fellow eye, Losing &gt;= 10 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12:fellow eye, Losing &gt;= 5 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12:fellow eye, Losing &lt;5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M18:Study eye, Losing &gt; 30 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M18:Study eye, Losing &gt;= 15 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M18:Study eye, Losing &gt;= 10 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M18:Study eye, Losing &gt;= 5 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M18:Study eye, Losing &lt;5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M18:fellow eye, Losing &gt; 30 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M18:fellow eye, Losing &gt;= 15 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M18:fellow eye, Losing &gt;= 10 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M18:fellow eye, Losing &gt;= 5 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M18:fellow eye, Losing &lt;5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in ETDRS-BCVA Score From Baseline at Every Month up to Month 18</title>
        <description>Participants enrolled into the study were required to have a best-corrected ETDRS visual acuity score of at least 35 letters as determined by ETDRS-BCVA evaluation. ETDRS-BCVA score was assessed as change from baseline in the mean best-corrected ETDRS visual acuity score at 18 months. Change from Baseline is defined as post-dose visit value minus Baseline value. Note that screening occurs before baseline. Values were truncated to one decimal place and negative sign retained where value is negative and the truncated value is zero. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
        <time_frame>Baseline and every month up to Month 18</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo (0.9 percent sodium chloride) by intravenous (IV) infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O2">
            <title>GSK933776 (3 mg/kg)</title>
            <description>Participants received 3 milligram (mg)/kilogram (kg) GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O3">
            <title>GSK933776 (6 mg/kg)</title>
            <description>Participants received 6 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O4">
            <title>GSK933776 (15 mg/kg)</title>
            <description>Participants received 15 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in ETDRS-BCVA Score From Baseline at Every Month up to Month 18</title>
          <description>Participants enrolled into the study were required to have a best-corrected ETDRS visual acuity score of at least 35 letters as determined by ETDRS-BCVA evaluation. ETDRS-BCVA score was assessed as change from baseline in the mean best-corrected ETDRS visual acuity score at 18 months. Change from Baseline is defined as post-dose visit value minus Baseline value. Note that screening occurs before baseline. Values were truncated to one decimal place and negative sign retained where value is negative and the truncated value is zero. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
          <population>ITT Population</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study eye, screening, n=46,46,48,48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="5.76"/>
                    <measurement group_id="O2" value="2.6" spread="6.31"/>
                    <measurement group_id="O3" value="0.6" spread="7.69"/>
                    <measurement group_id="O4" value="0.1" spread="8.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study eye, month 1, n=44,44,44,44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="4.77"/>
                    <measurement group_id="O2" value="0.3" spread="5.13"/>
                    <measurement group_id="O3" value="0.4" spread="5.02"/>
                    <measurement group_id="O4" value="-1.3" spread="5.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study eye, month 2, n=44,43,43,43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="7.09"/>
                    <measurement group_id="O2" value="1.0" spread="4.68"/>
                    <measurement group_id="O3" value="1.2" spread="4.45"/>
                    <measurement group_id="O4" value="-0.3" spread="6.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study eye, month 3, n=43,37,42,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="6.57"/>
                    <measurement group_id="O2" value="0.5" spread="7.53"/>
                    <measurement group_id="O3" value="1.0" spread="5.86"/>
                    <measurement group_id="O4" value="-0.0" spread="6.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study eye, month 4, n=43,36,42,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="7.93"/>
                    <measurement group_id="O2" value="1.6" spread="6.72"/>
                    <measurement group_id="O3" value="0.3" spread="6.00"/>
                    <measurement group_id="O4" value="-1.4" spread="8.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study eye, month 5, n=43,36,39, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="9.03"/>
                    <measurement group_id="O2" value="0.5" spread="6.60"/>
                    <measurement group_id="O3" value="2.2" spread="4.88"/>
                    <measurement group_id="O4" value="-2.6" spread="9.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study eye, month 6, n=43,36,40,40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="9.90"/>
                    <measurement group_id="O2" value="1.1" spread="6.91"/>
                    <measurement group_id="O3" value="1.6" spread="6.55"/>
                    <measurement group_id="O4" value="-1.0" spread="7.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study eye, month 7, n=43,36,40,40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="10.49"/>
                    <measurement group_id="O2" value="1.4" spread="7.04"/>
                    <measurement group_id="O3" value="1.1" spread="8.35"/>
                    <measurement group_id="O4" value="-1.7" spread="7.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study eye, month 8, n=42,33,40,40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0" spread="11.07"/>
                    <measurement group_id="O2" value="1.5" spread="5.94"/>
                    <measurement group_id="O3" value="0.6" spread="8.26"/>
                    <measurement group_id="O4" value="-3.4" spread="8.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study eye, month 9, n=41,33,40,40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="10.90"/>
                    <measurement group_id="O2" value="1.0" spread="5.97"/>
                    <measurement group_id="O3" value="1.3" spread="7.39"/>
                    <measurement group_id="O4" value="-2.2" spread="8.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study eye, month 10, n=41,32,40,40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="11.12"/>
                    <measurement group_id="O2" value="-0.6" spread="7.40"/>
                    <measurement group_id="O3" value="0.7" spread="10.05"/>
                    <measurement group_id="O4" value="-3.3" spread="9.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study eye, month 11, n=41,33,40,40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="11.69"/>
                    <measurement group_id="O2" value="0.1" spread="6.77"/>
                    <measurement group_id="O3" value="-0.6" spread="8.87"/>
                    <measurement group_id="O4" value="-4.1" spread="8.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study eye, month 12, n=39,30,38,38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="11.57"/>
                    <measurement group_id="O2" value="-0.4" spread="6.12"/>
                    <measurement group_id="O3" value="0.3" spread="9.94"/>
                    <measurement group_id="O4" value="-4.4" spread="9.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study eye, month 13, n=38,31,39,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="8.21"/>
                    <measurement group_id="O2" value="-0.1" spread="6.89"/>
                    <measurement group_id="O3" value="-0.9" spread="9.93"/>
                    <measurement group_id="O4" value="-4.2" spread="9.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study eye, month 14, n=38,31,35,35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="10.84"/>
                    <measurement group_id="O2" value="-0.2" spread="8.12"/>
                    <measurement group_id="O3" value="-1.2" spread="10.46"/>
                    <measurement group_id="O4" value="-3.8" spread="9.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study eye, month 15, n=37,31,35,35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="11.13"/>
                    <measurement group_id="O2" value="-1.7" spread="9.09"/>
                    <measurement group_id="O3" value="-2.4" spread="11.33"/>
                    <measurement group_id="O4" value="-4.0" spread="9.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study eye, month 16, n=37,31,35,35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="10.06"/>
                    <measurement group_id="O2" value="-2.1" spread="8.71"/>
                    <measurement group_id="O3" value="-2.2" spread="12.48"/>
                    <measurement group_id="O4" value="-3.9" spread="9.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study eye, month 17, n=38,32,36,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="14.56"/>
                    <measurement group_id="O2" value="-1.9" spread="8.33"/>
                    <measurement group_id="O3" value="-1.3" spread="11.85"/>
                    <measurement group_id="O4" value="-3.9" spread="9.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study eye, month 18, n=37,31,33,33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="11.58"/>
                    <measurement group_id="O2" value="-2.2" spread="10.61"/>
                    <measurement group_id="O3" value="-3.6" spread="15.05"/>
                    <measurement group_id="O4" value="-4.4" spread="9.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fellow eye, screening, n=46,45,46,51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0" spread="6.74"/>
                    <measurement group_id="O2" value="1.0" spread="8.30"/>
                    <measurement group_id="O3" value="0.7" spread="6.81"/>
                    <measurement group_id="O4" value="0.4" spread="9.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fellow eye, month 1, n=44,44,43,51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="5.01"/>
                    <measurement group_id="O2" value="1.6" spread="6.22"/>
                    <measurement group_id="O3" value="0.3" spread="5.52"/>
                    <measurement group_id="O4" value="-0.8" spread="7.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fellow eye, month 2, n=44,43,42,49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="5.61"/>
                    <measurement group_id="O2" value="2.3" spread="7.21"/>
                    <measurement group_id="O3" value="1.4" spread="5.50"/>
                    <measurement group_id="O4" value="1.0" spread="8.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fellow eye, month 3, n=43,37,41,46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="7.73"/>
                    <measurement group_id="O2" value="2.3" spread="8.01"/>
                    <measurement group_id="O3" value="1.2" spread="6.63"/>
                    <measurement group_id="O4" value="2.0" spread="6.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fellow eye, month 4, n=43,36,41,46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="8.32"/>
                    <measurement group_id="O2" value="3.6" spread="7.80"/>
                    <measurement group_id="O3" value="2.6" spread="7.95"/>
                    <measurement group_id="O4" value="1.1" spread="6.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fellow eye, month 5, n=43,36,38,46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="8.13"/>
                    <measurement group_id="O2" value="3.6" spread="9.47"/>
                    <measurement group_id="O3" value="1.5" spread="8.01"/>
                    <measurement group_id="O4" value="1.8" spread="5.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fellow eye, month 6, n=43,36,39,43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="11.62"/>
                    <measurement group_id="O2" value="3.2" spread="8.81"/>
                    <measurement group_id="O3" value="3.4" spread="6.55"/>
                    <measurement group_id="O4" value="2.8" spread="7.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fellow eye, month 7, n=43,36,39,44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="13.15"/>
                    <measurement group_id="O2" value="3.5" spread="8.70"/>
                    <measurement group_id="O3" value="3.3" spread="7.01"/>
                    <measurement group_id="O4" value="1.9" spread="6.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fellow eye, month 8, n=42,33,39,44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="14.53"/>
                    <measurement group_id="O2" value="3.2" spread="7.08"/>
                    <measurement group_id="O3" value="1.2" spread="7.75"/>
                    <measurement group_id="O4" value="2.6" spread="8.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fellow eye, month 9, n=41,33,39,44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="12.42"/>
                    <measurement group_id="O2" value="4.5" spread="7.12"/>
                    <measurement group_id="O3" value="2.7" spread="7.28"/>
                    <measurement group_id="O4" value="3.0" spread="7.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fellow eye, month 10, n=41, 32,39,44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="14.22"/>
                    <measurement group_id="O2" value="4.2" spread="7.58"/>
                    <measurement group_id="O3" value="2.4" spread="8.61"/>
                    <measurement group_id="O4" value="1.2" spread="9.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fellow eye, month 11, n=41,33,39,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="12.57"/>
                    <measurement group_id="O2" value="2.5" spread="7.96"/>
                    <measurement group_id="O3" value="1.0" spread="9.05"/>
                    <measurement group_id="O4" value="2.7" spread="7.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fellow eye, month 12, n=39,30,37,41</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="13.48"/>
                    <measurement group_id="O2" value="3.2" spread="8.58"/>
                    <measurement group_id="O3" value="2.7" spread="7.36"/>
                    <measurement group_id="O4" value="0.5" spread="10.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fellow eye, month 13, n=38,31,37,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="13.62"/>
                    <measurement group_id="O2" value="3.7" spread="7.92"/>
                    <measurement group_id="O3" value="1.8" spread="7.15"/>
                    <measurement group_id="O4" value="2.1" spread="8.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fellow eye, month 14, n=38,31,34,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="13.22"/>
                    <measurement group_id="O2" value="1.8" spread="11.85"/>
                    <measurement group_id="O3" value="2.9" spread="7.65"/>
                    <measurement group_id="O4" value="1.9" spread="7.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fellow eye, month 15, n=37,31,34,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="13.44"/>
                    <measurement group_id="O2" value="1.7" spread="8.13"/>
                    <measurement group_id="O3" value="2.3" spread="7.28"/>
                    <measurement group_id="O4" value="2.3" spread="6.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fellow eye, month 16, n=37,31,34,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="12.27"/>
                    <measurement group_id="O2" value="2.0" spread="9.42"/>
                    <measurement group_id="O3" value="2.9" spread="8.42"/>
                    <measurement group_id="O4" value="2.4" spread="7.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fellow eye, month 17, n=38,32,35,40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="13.53"/>
                    <measurement group_id="O2" value="2.7" spread="9.55"/>
                    <measurement group_id="O3" value="1.6" spread="9.32"/>
                    <measurement group_id="O4" value="1.6" spread="8.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fellow eye, month 18, n=37,31,32,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="13.12"/>
                    <measurement group_id="O2" value="1.2" spread="10.01"/>
                    <measurement group_id="O3" value="2.5" spread="8.98"/>
                    <measurement group_id="O4" value="0.4" spread="8.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve From Time 0 to the End of Dosing Interval at Steady-state (AUC0-28d) of GSK933776 in Geographic Atrophy Participants</title>
        <description>Area under the plasma concentration-time curve from time 0 to the end of dosing interval at steady-state; derived from dose and clearance parameters was evaluated. Blood samples were collected at the indicated time points on Day 56, Day 63, 70 or 77, Day 84, Day 112, Day 140, Day 224, Day 308, Day 392 and Day 476.</description>
        <time_frame>Day 56, Day 63, 70 or 77, Day 84, Day 112, Day 140, Day 224, Day 308, Day 392 and Day 476</time_frame>
        <population>Pharmacokinetic (PK) Parameter Population: all participants in the ITT Population with derived PK parameters</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo (0.9 percent sodium chloride) by intravenous (IV) infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O2">
            <title>GSK933776 (3 mg/kg)</title>
            <description>Participants received 3 milligram (mg)/kilogram (kg) GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O3">
            <title>GSK933776 (6 mg/kg)</title>
            <description>Participants received 6 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O4">
            <title>GSK933776 (15 mg/kg)</title>
            <description>Participants received 15 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Time 0 to the End of Dosing Interval at Steady-state (AUC0-28d) of GSK933776 in Geographic Atrophy Participants</title>
          <description>Area under the plasma concentration-time curve from time 0 to the end of dosing interval at steady-state; derived from dose and clearance parameters was evaluated. Blood samples were collected at the indicated time points on Day 56, Day 63, 70 or 77, Day 84, Day 112, Day 140, Day 224, Day 308, Day 392 and Day 476.</description>
          <population>Pharmacokinetic (PK) Parameter Population: all participants in the ITT Population with derived PK parameters</population>
          <units>microgram (mcg)*hours (h)/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="16725.96" lower_limit="15814.25" upper_limit="17690.24"/>
                    <measurement group_id="O3" value="29717.17" lower_limit="28241.55" upper_limit="31269.90"/>
                    <measurement group_id="O4" value="69485.24" lower_limit="66687.22" upper_limit="72400.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) and Pre-dose (Trough) Concentration at the End of the Dosing Interval (Ctau) of GSK933776 in Geographic Atrophy Participants</title>
        <description>Blood samples were collected at the indicated time points on Day 56, Day 63, 70 or 77, Day 84, Day 112, Day 140, Day 224, Day 308, Day 392 and Day 476</description>
        <time_frame>Day 56, Day 63, 70 or 77, Day 84, Day 112, Day 140, Day 224, Day 308, Day 392 and Day 476</time_frame>
        <population>PK Parameter Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo (0.9 percent sodium chloride) by intravenous (IV) infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O2">
            <title>GSK933776 (3 mg/kg)</title>
            <description>Participants received 3 milligram (mg)/kilogram (kg) GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O3">
            <title>GSK933776 (6 mg/kg)</title>
            <description>Participants received 6 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O4">
            <title>GSK933776 (15 mg/kg)</title>
            <description>Participants received 15 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) and Pre-dose (Trough) Concentration at the End of the Dosing Interval (Ctau) of GSK933776 in Geographic Atrophy Participants</title>
          <description>Blood samples were collected at the indicated time points on Day 56, Day 63, 70 or 77, Day 84, Day 112, Day 140, Day 224, Day 308, Day 392 and Day 476</description>
          <population>PK Parameter Population</population>
          <units>nanogram (ng)/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="82311.15" lower_limit="73272.43" upper_limit="92464.87"/>
                    <measurement group_id="O3" value="142728.2" lower_limit="126308.3" upper_limit="161282.8"/>
                    <measurement group_id="O4" value="350716.9" lower_limit="314882.9" upper_limit="390628.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ctau</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="8551.70" lower_limit="7565.08" upper_limit="9667.00"/>
                    <measurement group_id="O3" value="15512.19" lower_limit="13721.27" upper_limit="17536.86"/>
                    <measurement group_id="O4" value="37589.25" lower_limit="33641.86" upper_limit="41999.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clearance (CL) of GSK933776 in Geographic Atrophy Participants</title>
        <description>Blood samples were collected at the indicated time points on Day 56, Day 63, 70 or 77, Day 84, Day 112, Day 140, Day 224, Day 308, Day 392 and Day 476.</description>
        <time_frame>Day 56, Day 63, 70 or 77, Day 84, Day 112, Day 140, Day 224, Day 308, Day 392 and Day 476</time_frame>
        <population>PK Parameter Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo (0.9 percent sodium chloride) by intravenous (IV) infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O2">
            <title>GSK933776 (3 mg/kg)</title>
            <description>Participants received 3 milligram (mg)/kilogram (kg) GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O3">
            <title>GSK933776 (6 mg/kg)</title>
            <description>Participants received 6 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O4">
            <title>GSK933776 (15 mg/kg)</title>
            <description>Participants received 15 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance (CL) of GSK933776 in Geographic Atrophy Participants</title>
          <description>Blood samples were collected at the indicated time points on Day 56, Day 63, 70 or 77, Day 84, Day 112, Day 140, Day 224, Day 308, Day 392 and Day 476.</description>
          <population>PK Parameter Population</population>
          <units>mL/h</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="14.66" lower_limit="13.87" upper_limit="15.49"/>
                    <measurement group_id="O3" value="14.90" lower_limit="13.93" upper_limit="15.94"/>
                    <measurement group_id="O4" value="16.09" lower_limit="15.16" upper_limit="17.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimation of Terminal Phase Half-life (T1/2) of GSK933776 in Geographic Atrophy Participants</title>
        <description>Blood samples were collected at the indicated time points on Day 56, Day 63, 70 or 77, Day 84, Day 112, Day 140, Day 224, Day 308, Day 392 and Day 476.</description>
        <time_frame>Day 56, Day 63, 70 or 77, Day 84, Day 112, Day 140, Day 224, Day 308, Day 392 and Day 476</time_frame>
        <population>PK Parameter Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo (0.9 percent sodium chloride) by intravenous (IV) infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O2">
            <title>GSK933776 (3 mg/kg)</title>
            <description>Participants received 3 milligram (mg)/kilogram (kg) GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O3">
            <title>GSK933776 (6 mg/kg)</title>
            <description>Participants received 6 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O4">
            <title>GSK933776 (15 mg/kg)</title>
            <description>Participants received 15 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Estimation of Terminal Phase Half-life (T1/2) of GSK933776 in Geographic Atrophy Participants</title>
          <description>Blood samples were collected at the indicated time points on Day 56, Day 63, 70 or 77, Day 84, Day 112, Day 140, Day 224, Day 308, Day 392 and Day 476.</description>
          <population>PK Parameter Population</population>
          <units>Days</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="11.67" lower_limit="11.37" upper_limit="11.98"/>
                    <measurement group_id="O3" value="11.87" lower_limit="11.52" upper_limit="12.24"/>
                    <measurement group_id="O4" value="11.27" lower_limit="10.93" upper_limit="11.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution at Steady-state (Vdss) of GSK933776 in Geographic Atrophy Participants Estimated From Population PK Modeling</title>
        <description>Blood samples were collected at the indicated time points on Day 56, Day 63, 70 or 77, Day 84, Day 112, Day 140, Day 224, Day 308, Day 392 and Day 476.</description>
        <time_frame>Day 56, Day 63, 70 or 77, Day 84, Day 112, Day 140, Day 224, Day 308, Day 392 and Day 476</time_frame>
        <population>PK Parameter Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo (0.9 percent sodium chloride) by intravenous (IV) infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O2">
            <title>GSK933776 (3 mg/kg)</title>
            <description>Participants received 3 milligram (mg)/kilogram (kg) GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O3">
            <title>GSK933776 (6 mg/kg)</title>
            <description>Participants received 6 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O4">
            <title>GSK933776 (15 mg/kg)</title>
            <description>Participants received 15 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution at Steady-state (Vdss) of GSK933776 in Geographic Atrophy Participants Estimated From Population PK Modeling</title>
          <description>Blood samples were collected at the indicated time points on Day 56, Day 63, 70 or 77, Day 84, Day 112, Day 140, Day 224, Day 308, Day 392 and Day 476.</description>
          <population>PK Parameter Population</population>
          <units>mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="5618.72" lower_limit="5417.37" upper_limit="5827.55"/>
                    <measurement group_id="O3" value="5825.03" lower_limit="5569.75" upper_limit="6092.02"/>
                    <measurement group_id="O4" value="5959.42" lower_limit="5730.63" upper_limit="6197.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Pharmacodynamic Effects of GSK933776 Total (Bound and Unbound) Plasma Total Amyloid Beta (Abeta42), and Amyloid Beta Fragments (Abeta18-35), if Possible, Unbound Plasma Aβ Fragments (Abeta1-22)</title>
        <description>Blood samples were collected at the indicated time points on Baseline, Month 3, Month 4, Month 5, Month 6, Month 9, Month 12, Month 15 and Month 18. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
        <time_frame>Baseline, Month 3, Month 4, Month 5, Month 6, Month 9, Month 12, Month 15 and Month 18</time_frame>
        <population>PD Concentration Population: all participants in the ITT Population with at least one PD sample</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo (0.9 percent sodium chloride) by intravenous (IV) infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O2">
            <title>GSK933776 (3 mg/kg)</title>
            <description>Participants received 3 milligram (mg)/kilogram (kg) GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O3">
            <title>GSK933776 (6 mg/kg)</title>
            <description>Participants received 6 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
          <group group_id="O4">
            <title>GSK933776 (15 mg/kg)</title>
            <description>Participants received 15 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
          </group>
        </group_list>
        <measure>
          <title>The Pharmacodynamic Effects of GSK933776 Total (Bound and Unbound) Plasma Total Amyloid Beta (Abeta42), and Amyloid Beta Fragments (Abeta18-35), if Possible, Unbound Plasma Aβ Fragments (Abeta1-22)</title>
          <description>Blood samples were collected at the indicated time points on Baseline, Month 3, Month 4, Month 5, Month 6, Month 9, Month 12, Month 15 and Month 18. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
          <population>PD Concentration Population: all participants in the ITT Population with at least one PD sample</population>
          <units>picogram (PG)/ML</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ab1-22 Baseline, n=45,42,46,48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="715.69" spread="237.06"/>
                    <measurement group_id="O2" value="702.63" spread="278.771"/>
                    <measurement group_id="O3" value="729.12" spread="260.094"/>
                    <measurement group_id="O4" value="709.04" spread="205.697"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab1-22 month 3, PD, n=41,39,39, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="675.95" spread="158.88"/>
                    <measurement group_id="O2" value="833.22" spread="557.283"/>
                    <measurement group_id="O3" value="721.04" spread="436.777"/>
                    <measurement group_id="O4" value="756.85" spread="367.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab1-22, month 3, 1H post, n=40,39,36,44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="706.74" spread="159.38"/>
                    <measurement group_id="O2" value="101.59" spread="88.045"/>
                    <measurement group_id="O3" value="86.57" spread="76.641"/>
                    <measurement group_id="O4" value="73.29" spread="115.732"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab1-22, month 3, 3H post, n=40,39,37,43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="707.00" spread="168.67"/>
                    <measurement group_id="O2" value="142.63" spread="144.798"/>
                    <measurement group_id="O3" value="92.22" spread="80.565"/>
                    <measurement group_id="O4" value="67.42" spread="50.512"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab1-22, month 3, 7 D post M3, n=9,12,14,9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="701.59" spread="232.76"/>
                    <measurement group_id="O2" value="571.23" spread="445.822"/>
                    <measurement group_id="O3" value="438.53" spread="270.154"/>
                    <measurement group_id="O4" value="274.57" spread="190.397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab1-22, month 3, 14 D post M3, n=9,9,6,14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="825.32" spread="197.52"/>
                    <measurement group_id="O2" value="587.33" spread="364.383"/>
                    <measurement group_id="O3" value="357.47" spread="228.729"/>
                    <measurement group_id="O4" value="444.97" spread="149.504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab1-22, month 3, 21 D post M3, n=23,15, 18,22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="592.13" spread="205.75"/>
                    <measurement group_id="O2" value="669.63" spread="377.229"/>
                    <measurement group_id="O3" value="730.61" spread="419.034"/>
                    <measurement group_id="O4" value="674.38" spread="270.355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab1-22 month 4, PD, n=39,32,39,44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="671.16" spread="207.78"/>
                    <measurement group_id="O2" value="798.93" spread="588.940"/>
                    <measurement group_id="O3" value="763.67" spread="468.654"/>
                    <measurement group_id="O4" value="811.97" spread="300.797"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab1-22, month 4, 1 H post, n=38,30,37,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="681.64" spread="245.28"/>
                    <measurement group_id="O2" value="95.12" spread="101.607"/>
                    <measurement group_id="O3" value="114.68" spread="142.473"/>
                    <measurement group_id="O4" value="57.27" spread="33.590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab1-22, month 4, 3 H post, n=38,31,35,41</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="713.41" spread="213.60"/>
                    <measurement group_id="O2" value="113.68" spread="120.182"/>
                    <measurement group_id="O3" value="104.79" spread="85.438"/>
                    <measurement group_id="O4" value="64.05" spread="36.625"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab1-22 month 5, PD, n=38,29,38,46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="686.71" spread="242.20"/>
                    <measurement group_id="O2" value="876.62" spread="587.141"/>
                    <measurement group_id="O3" value="725.24" spread="432.365"/>
                    <measurement group_id="O4" value="829.03" spread="374.933"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab1-22, month 5, 1 H post, n=38,30,37,43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="671.58" spread="263.41"/>
                    <measurement group_id="O2" value="106.23" spread="117.776"/>
                    <measurement group_id="O3" value="113.36" spread="114.519"/>
                    <measurement group_id="O4" value="52.91" spread="31.684"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab1-22, month 5, 3 H post, n=38,29,36,43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="680.31" spread="233.46"/>
                    <measurement group_id="O2" value="131.86" spread="128.104"/>
                    <measurement group_id="O3" value="99.54" spread="87.204"/>
                    <measurement group_id="O4" value="93.08" spread="227.209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab1-22 month 6, PD, n=36,31,35,45</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="664.05" spread="286.35"/>
                    <measurement group_id="O2" value="944.83" spread="666.482"/>
                    <measurement group_id="O3" value="786.00" spread="395.099"/>
                    <measurement group_id="O4" value="796.74" spread="321.794"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab1-22, month 6, 1 H post, n=35,30,32,43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="745.27" spread="262.59"/>
                    <measurement group_id="O2" value="98.90" spread="89.639"/>
                    <measurement group_id="O3" value="87.87" spread="76.150"/>
                    <measurement group_id="O4" value="60.33" spread="45.976"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab1-22, month 6, 3 H post, n=36,30,31,43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="717.93" spread="255.49"/>
                    <measurement group_id="O2" value="127.41" spread="114.486"/>
                    <measurement group_id="O3" value="101.20" spread="79.938"/>
                    <measurement group_id="O4" value="93.26" spread="209.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab1-22 month 9, PD, n=38,28,34,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="698.54" spread="231.31"/>
                    <measurement group_id="O2" value="965.46" spread="664.425"/>
                    <measurement group_id="O3" value="731.34" spread="460.298"/>
                    <measurement group_id="O4" value="710.63" spread="313.891"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab1-22, month 9, 1 H post, n=37,28,34,41</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="749.19" spread="230.82"/>
                    <measurement group_id="O2" value="187.83" spread="206.605"/>
                    <measurement group_id="O3" value="93.58" spread="103.359"/>
                    <measurement group_id="O4" value="51.96" spread="33.876"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab1-22, month 9, 3 H post, n=37,26,34,40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="706.89" spread="259.60"/>
                    <measurement group_id="O2" value="172.30" spread="159.749"/>
                    <measurement group_id="O3" value="101.28" spread="103.129"/>
                    <measurement group_id="O4" value="54.65" spread="36.712"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab1-22 month 12, PD, n=38,30,37,41</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="688.50" spread="183.35"/>
                    <measurement group_id="O2" value="980.25" spread="342.607"/>
                    <measurement group_id="O3" value="724.92" spread="366.266"/>
                    <measurement group_id="O4" value="669.94" spread="417.194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab1-22, month 12, 1 H post, n=37,30,34,38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="687.88" spread="203.57"/>
                    <measurement group_id="O2" value="87.34" spread="74.521"/>
                    <measurement group_id="O3" value="68.86" spread="77.852"/>
                    <measurement group_id="O4" value="55.36" spread="46.136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab1-22, month 12, 3 H post, n=37,31,31,37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="680.21" spread="221.73"/>
                    <measurement group_id="O2" value="162.41" spread="231.741"/>
                    <measurement group_id="O3" value="79.92" spread="78.323"/>
                    <measurement group_id="O4" value="56.04" spread="48.351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab1-22 month 15, PD, n=36,27,31,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="667.13" spread="279.48"/>
                    <measurement group_id="O2" value="1011.37" spread="458.087"/>
                    <measurement group_id="O3" value="877.55" spread="589.463"/>
                    <measurement group_id="O4" value="451.65" spread="310.992"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab1-22, month 15, 1 H post, n=38,28,32,38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="674.94" spread="272.43"/>
                    <measurement group_id="O2" value="102.84" spread="69.049"/>
                    <measurement group_id="O3" value="92.10" spread="109.355"/>
                    <measurement group_id="O4" value="52.10" spread="89.673"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab1-22, month 15, 3 H post, n=36,27,29,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="664.14" spread="321.47"/>
                    <measurement group_id="O2" value="135.58" spread="78.565"/>
                    <measurement group_id="O3" value="120.82" spread="124.908"/>
                    <measurement group_id="O4" value="54.85" spread="76.984"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab1-22 month 18, PD, n=35,28,34,38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="562.41" spread="186.57"/>
                    <measurement group_id="O2" value="1019.37" spread="510.656"/>
                    <measurement group_id="O3" value="968.23" spread="582.016"/>
                    <measurement group_id="O4" value="396.39" spread="324.875"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab1-22, month 18, 1 H post, n=35,27,33,37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="603.70" spread="184.05"/>
                    <measurement group_id="O2" value="94.79" spread="54.323"/>
                    <measurement group_id="O3" value="93.83" spread="77.725"/>
                    <measurement group_id="O4" value="42.40" spread="37.672"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab1-22, month 18, 3 H post, n=34,26,32,37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="572.09" spread="161.77"/>
                    <measurement group_id="O2" value="127.62" spread="67.299"/>
                    <measurement group_id="O3" value="103.38" spread="84.009"/>
                    <measurement group_id="O4" value="38.60" spread="22.256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab 18-34 Baseline, n=43,37,45,38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="743.82" spread="380.653"/>
                    <measurement group_id="O2" value="819.49" spread="296.673"/>
                    <measurement group_id="O3" value="743.81" spread="406.171"/>
                    <measurement group_id="O4" value="579.25" spread="277.483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab 18-34 month 3, PD, n=39,38,37,45</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="785.65" spread="454.869"/>
                    <measurement group_id="O2" value="18592.94" spread="5597.893"/>
                    <measurement group_id="O3" value="27957.34" spread="8921.484"/>
                    <measurement group_id="O4" value="33131.16" spread="11098.580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab 18-34, month 3, 1H post, n=39,38,33,43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1408.61" spread="3774.763"/>
                    <measurement group_id="O2" value="22652.19" spread="6213.219"/>
                    <measurement group_id="O3" value="31669.84" spread="9225.846"/>
                    <measurement group_id="O4" value="34207.81" spread="11060.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab 18-34, month 3, 3H post, n=37,38,32,43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="836.20" spread="429.027"/>
                    <measurement group_id="O2" value="26215.58" spread="7838.227"/>
                    <measurement group_id="O3" value="34779.13" spread="9115.431"/>
                    <measurement group_id="O4" value="38141.47" spread="9668.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab 18-34, month 3, 7 D post M3, n=7,11,11,8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="922.92" spread="370.492"/>
                    <measurement group_id="O2" value="44763.87" spread="6895.501"/>
                    <measurement group_id="O3" value="56154.01" spread="13944.00"/>
                    <measurement group_id="O4" value="49791.95" spread="16363.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab 18-34, month 3, 14 D post M3, n=9,11,4,14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1068.33" spread="779.813"/>
                    <measurement group_id="O2" value="35763.55" spread="6062.090"/>
                    <measurement group_id="O3" value="38729.93" spread="7646.892"/>
                    <measurement group_id="O4" value="41809.21" spread="12065.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab 18-34, month 3, 21 D post M3, n=18,15,16,20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="811.92" spread="321.961"/>
                    <measurement group_id="O2" value="21020.41" spread="9021.023"/>
                    <measurement group_id="O3" value="35400.30" spread="7979.633"/>
                    <measurement group_id="O4" value="43914.27" spread="11231.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab 18-34 month 4, PD, n=35,31,35,</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="894.86" spread="443.914"/>
                    <measurement group_id="O2" value="17268.05" spread="5857.907"/>
                    <measurement group_id="O3" value="26716.77" spread="10948.73"/>
                    <measurement group_id="O4" value="33334.70" spread="8458.286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab 18-34, month 4, 1 H post, n=32,31,33,41</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="885.66" spread="377.125"/>
                    <measurement group_id="O2" value="20994.88" spread="6978.372"/>
                    <measurement group_id="O3" value="29940.66" spread="10073.83"/>
                    <measurement group_id="O4" value="34964.84" spread="10002.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab 18-34, month 4, 3 H post, n=32,31,31,40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="881.00" spread="347.112"/>
                    <measurement group_id="O2" value="24894.01" spread="7706.804"/>
                    <measurement group_id="O3" value="32626.1" spread="10801.42"/>
                    <measurement group_id="O4" value="37516.27" spread="10955.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab 18-34 month 5, PD, n=33,28,35, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="951.92" spread="516.887"/>
                    <measurement group_id="O2" value="18728.68" spread="6760.913"/>
                    <measurement group_id="O3" value="27358.59" spread="11742.90"/>
                    <measurement group_id="O4" value="32652.34" spread="9462.231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab 18-34, month 5, 1 H post, n=34,28,35,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="962.84" spread="490.933"/>
                    <measurement group_id="O2" value="23681.97" spread="7190.390"/>
                    <measurement group_id="O3" value="29660.64" spread="10276.52"/>
                    <measurement group_id="O4" value="33182.12" spread="9115.903"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab 18-34, month 5, 3 H post, n=36,28,34,40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="893.16" spread="485.544"/>
                    <measurement group_id="O2" value="25711.80" spread="6767.509"/>
                    <measurement group_id="O3" value="33735.73" spread="12433.44"/>
                    <measurement group_id="O4" value="34169.47" spread="8984.387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab 18-34 month 6, PD, n=34,29,35,45</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="838.42" spread="425.702"/>
                    <measurement group_id="O2" value="18801.95" spread="7605.319"/>
                    <measurement group_id="O3" value="30073.49" spread="11286.35"/>
                    <measurement group_id="O4" value="32538.92" spread="8469.383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab 18-34, month 6, 1 H post, n=33,28,33,43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1566.28" spread="4065.365"/>
                    <measurement group_id="O2" value="22511.14" spread="7848.044"/>
                    <measurement group_id="O3" value="33259.36" spread="10975.41"/>
                    <measurement group_id="O4" value="34146.93" spread="10421.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab 18-34, month 6, 3 H post, n=32,29,32,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="846.19" spread="421.980"/>
                    <measurement group_id="O2" value="26457.65" spread="7860.423"/>
                    <measurement group_id="O3" value="37724.75" spread="12990.61"/>
                    <measurement group_id="O4" value="37139.56" spread="12656.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab 18-34 month 9, PD, n=33,22,33,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="609.41" spread="329.151"/>
                    <measurement group_id="O2" value="18187.69" spread="6942.978"/>
                    <measurement group_id="O3" value="27101.57" spread="11334.69"/>
                    <measurement group_id="O4" value="33653.88" spread="12115.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab 18-34, month 9, 1 H post, n=33,23,32,40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="617.63" spread="339.050"/>
                    <measurement group_id="O2" value="22315.06" spread="8256.360"/>
                    <measurement group_id="O3" value="29347.65" spread="11567.85"/>
                    <measurement group_id="O4" value="34807.59" spread="11458.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab 18-34, month 9, 3 H post, n=</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1503.09" spread="4809.095"/>
                    <measurement group_id="O2" value="26238.37" spread="8950.567"/>
                    <measurement group_id="O3" value="31788.45" spread="12230.14"/>
                    <measurement group_id="O4" value="37923.17" spread="13928.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab 18-34 month 12, PD, n=32,22,33,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="565.11" spread="269.418"/>
                    <measurement group_id="O2" value="15213.11" spread="7350.114"/>
                    <measurement group_id="O3" value="24193.39" spread="10117.95"/>
                    <measurement group_id="O4" value="33105.49" spread="9358.291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab 18-34, month 12, 1 H post, n=37,29,36,40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="555.39" spread="296.989"/>
                    <measurement group_id="O2" value="21439.13" spread="9174.242"/>
                    <measurement group_id="O3" value="25724.20" spread="9073.725"/>
                    <measurement group_id="O4" value="35273.76" spread="11497.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab 18-34, month 12, 3 H post, n=35,29,33,37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1532.25" spread="5463.999"/>
                    <measurement group_id="O2" value="21295.72" spread="6471.001"/>
                    <measurement group_id="O3" value="28771.21" spread="9392.402"/>
                    <measurement group_id="O4" value="37831.60" spread="11953.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unscheduled, n=0,0,0,1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">NA indicates that no data is available for those Arms - only one sample for one participant was collected at the ‘Unscheduled' time point.</measurement>
                    <measurement group_id="O2" value="NA">NA indicates that no data is available for those Arms - only one sample for one participant was collected at the ‘Unscheduled' time point.</measurement>
                    <measurement group_id="O3" value="NA">NA indicates that no data is available for those Arms - only one sample for one participant was collected at the ‘Unscheduled' time point.</measurement>
                    <measurement group_id="O4" value="18312.40">NA indicates that the SD is not available due to only 1 participant analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab 18-34 month 15, PD, n=35,26,30,37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="461.47" spread="414.780"/>
                    <measurement group_id="O2" value="16852.93" spread="6707.423"/>
                    <measurement group_id="O3" value="22121.87" spread="7510.438"/>
                    <measurement group_id="O4" value="28887.86" spread="7891.499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab 18-34, month 15, 1 H post, n=30,27,31,37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="530.88" spread="392.825"/>
                    <measurement group_id="O2" value="20158.76" spread="7147.691"/>
                    <measurement group_id="O3" value="26219.44" spread="7873.201"/>
                    <measurement group_id="O4" value="28914.08" spread="9757.638"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab 18-34, month 15, 3 H post, n=26,25,30,33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="825.72" spread="1527.743"/>
                    <measurement group_id="O2" value="23509.29" spread="9303.296"/>
                    <measurement group_id="O3" value="29785.49" spread="9191.623"/>
                    <measurement group_id="O4" value="31653.02" spread="8909.182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab 18-34 month 18, PD, n=27,27,34,38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3144.40" spread="9209.436"/>
                    <measurement group_id="O2" value="14266.65" spread="7931.78"/>
                    <measurement group_id="O3" value="21134.85" spread="8638.106"/>
                    <measurement group_id="O4" value="28107.98" spread="9780.376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab 18-34, month 18, 1 H post, n=28,27,33,37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2988.76" spread="8357.739"/>
                    <measurement group_id="O2" value="18503.81" spread="9250.829"/>
                    <measurement group_id="O3" value="24124.61" spread="7723.055"/>
                    <measurement group_id="O4" value="29913.96" spread="10878.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab 18-34, month 18, 3 H post, n=28,27,32,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3144.44" spread="9129.569"/>
                    <measurement group_id="O2" value="21691.51" spread="8999.993"/>
                    <measurement group_id="O3" value="28580.63" spread="8684.780"/>
                    <measurement group_id="O4" value="31441.25" spread="10084.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab42 Baseline, n=38,39,41,20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.90" spread="173.673"/>
                    <measurement group_id="O2" value="92.27" spread="79.938"/>
                    <measurement group_id="O3" value="99.86" spread="85.958"/>
                    <measurement group_id="O4" value="384.28" spread="760.175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab42 month 3, PD, n=36,38,40, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167.67" spread="255.009"/>
                    <measurement group_id="O2" value="988.18" spread="370.001"/>
                    <measurement group_id="O3" value="1523.72" spread="662.292"/>
                    <measurement group_id="O4" value="1689.03" spread="652.829"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab42, month 3, 1H post, n= 35,38,37,37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.58" spread="230.115"/>
                    <measurement group_id="O2" value="1152.92" spread="420.811"/>
                    <measurement group_id="O3" value="1589.49" spread="629.616"/>
                    <measurement group_id="O4" value="1778.93" spread="644.677"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab42, month 3, 3H post, n=36,38,38,35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207.98" spread="345.712"/>
                    <measurement group_id="O2" value="1296.12" spread="438.252"/>
                    <measurement group_id="O3" value="1672.97" spread="664.08"/>
                    <measurement group_id="O4" value="1959.40" spread="707.293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab42, month 3, 7 D post M3, n=9,11,15,6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.61" spread="34.043"/>
                    <measurement group_id="O2" value="1697.51" spread="401.839"/>
                    <measurement group_id="O3" value="2022.63" spread="897.848"/>
                    <measurement group_id="O4" value="2007.92" spread="673.666"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab42, month 3, 14 D post M3, n=8,11,6,9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="244.51" spread="277.941"/>
                    <measurement group_id="O2" value="1599.87" spread="373.006"/>
                    <measurement group_id="O3" value="1608.36" spread="360.506"/>
                    <measurement group_id="O4" value="1695.08" spread="234.094"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab42, month 3, 21 D post M3, n=18,14, 18,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169.91" spread="368.921"/>
                    <measurement group_id="O2" value="1015.81" spread="394.872"/>
                    <measurement group_id="O3" value="1559.20" spread="469.99"/>
                    <measurement group_id="O4" value="2096.98" spread="769.107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab42 month 4, PD, n=35,33,39, 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195.41" spread="331.409"/>
                    <measurement group_id="O2" value="984.70" spread="329.701"/>
                    <measurement group_id="O3" value="1381.96" spread="666.242"/>
                    <measurement group_id="O4" value="1575.82" spread="606.059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab42, month 4, 1 H post, n=33,33,36,30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202.80" spread="338.066"/>
                    <measurement group_id="O2" value="1095.62" spread="348.452"/>
                    <measurement group_id="O3" value="1541.21" spread="657.964"/>
                    <measurement group_id="O4" value="1821.73" spread="817.436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab42, month 4, 3 H post, n=35,32,33,30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="201.34" spread="334.588"/>
                    <measurement group_id="O2" value="1313.46" spread="457.509"/>
                    <measurement group_id="O3" value="1714.54" spread="689.400"/>
                    <measurement group_id="O4" value="1744.84" spread="768.485"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab42 month 5, PD, n=33,32,39,34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186.73" spread="316.028"/>
                    <measurement group_id="O2" value="978.6" spread="403.364"/>
                    <measurement group_id="O3" value="1422.10" spread="620.253"/>
                    <measurement group_id="O4" value="1450.71" spread="599.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab42, month 5, 1 H post, n=33,32,40,32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182.94" spread="293.746"/>
                    <measurement group_id="O2" value="1214.53" spread="409.266"/>
                    <measurement group_id="O3" value="1526.11" spread="651.944"/>
                    <measurement group_id="O4" value="1572.92" spread="565.403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab42, month 5, 3 H post, n=32,31,39,31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177.67" spread="285.526"/>
                    <measurement group_id="O2" value="1351.07" spread="416.735"/>
                    <measurement group_id="O3" value="1755.13" spread="741.876"/>
                    <measurement group_id="O4" value="1696.91" spread="708.505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab42 month 6, PD, n=27,30,38,33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218.22" spread="418.144"/>
                    <measurement group_id="O2" value="1074.00" spread="495.245"/>
                    <measurement group_id="O3" value="1711.71" spread="1502.526"/>
                    <measurement group_id="O4" value="1509.95" spread="425.854"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab42, month 6, 1 H post, n=29,30,36,32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="233.29" spread="401.633"/>
                    <measurement group_id="O2" value="1241.12" spread="528.261"/>
                    <measurement group_id="O3" value="1835.47" spread="1447.740"/>
                    <measurement group_id="O4" value="1613.65" spread="493.896"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab42, month 6, 3 H post, n=27,32,34,31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="222.86" spread="435.218"/>
                    <measurement group_id="O2" value="1421.14" spread="545.844"/>
                    <measurement group_id="O3" value="2074.12" spread="1509.886"/>
                    <measurement group_id="O4" value="1723.03" spread="790.928"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab42 month 9, PD, n=19,27,37,38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191.73" spread="243.600"/>
                    <measurement group_id="O2" value="1049.44" spread="419.011"/>
                    <measurement group_id="O3" value="1650.02" spread="1809.009"/>
                    <measurement group_id="O4" value="1519.98" spread="842.690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab42, month 9, 1 H post, n=18,27,35,38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179.70" spread="212.048"/>
                    <measurement group_id="O2" value="1218.78" spread="390.582"/>
                    <measurement group_id="O3" value="1723.09" spread="1521.428"/>
                    <measurement group_id="O4" value="1591.82" spread="749.909"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab42, month 9, 3 H post, n=17,24,36,37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="201.73" spread="238.311"/>
                    <measurement group_id="O2" value="1420.29" spread="486.511"/>
                    <measurement group_id="O3" value="1857.20" spread="1642.287"/>
                    <measurement group_id="O4" value="1691.34" spread="854.596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab42 month 12, PD, n=13,27,37,37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200.69" spread="265.476"/>
                    <measurement group_id="O2" value="916.06" spread="451.841"/>
                    <measurement group_id="O3" value="1253.07" spread="566.682"/>
                    <measurement group_id="O4" value="1221.73" spread="504.928"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab42, month 12, 1 H post, n=14,26,33,34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190.76" spread="246.820"/>
                    <measurement group_id="O2" value="1211.53" spread="488.773"/>
                    <measurement group_id="O3" value="1383.67" spread="605.187"/>
                    <measurement group_id="O4" value="1324.37" spread="598.120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab42, month 12, 3 H post, n=15,27,30,34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193.7" spread="240.465"/>
                    <measurement group_id="O2" value="1238.51" spread="478.369"/>
                    <measurement group_id="O3" value="1489.97" spread="519.535"/>
                    <measurement group_id="O4" value="1411.51" spread="593.534"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab42 month 15, PD, n=11,27,30,37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="255.38" spread="510.410"/>
                    <measurement group_id="O2" value="1022.33" spread="415.974"/>
                    <measurement group_id="O3" value="1109.96" spread="467.439"/>
                    <measurement group_id="O4" value="1157.26" spread="347.208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab42, month 15, 1 H post, n=11,27,34,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241.82" spread="469.544"/>
                    <measurement group_id="O2" value="1181.69" spread="458.696"/>
                    <measurement group_id="O3" value="1266.70" spread="430.670"/>
                    <measurement group_id="O4" value="1172.10" spread="300.788"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab42, month 15, 3 H post, n=10,26,30,34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="272.83" spread="524.796"/>
                    <measurement group_id="O2" value="1360.57" spread="510.374"/>
                    <measurement group_id="O3" value="1488.49" spread="479.831"/>
                    <measurement group_id="O4" value="1257.99" spread="330.407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab42 month 18, PD, n=8,29,29,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.77" spread="106.936"/>
                    <measurement group_id="O2" value="722.52" spread="381.288"/>
                    <measurement group_id="O3" value="997.11" spread="438.328"/>
                    <measurement group_id="O4" value="1087.18" spread="270.541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab42, month 18, 1 H post, n=10,28,29,35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.29" spread="95.689"/>
                    <measurement group_id="O2" value="900.42" spread="434.525"/>
                    <measurement group_id="O3" value="1134.77" spread="439.660"/>
                    <measurement group_id="O4" value="1205.27" spread="389.468"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab42, month 18, 3 H post, n=10,28,27,35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.09" spread="88.111"/>
                    <measurement group_id="O2" value="1024.30" spread="472.320"/>
                    <measurement group_id="O3" value="1326.97" spread="491.829"/>
                    <measurement group_id="O4" value="1254.63" spread="304.826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events (SAEs) and non-serious AEs were collected from the start of study medication up to approximately 21 months.</time_frame>
      <desc>SAEs and non-serious AEs were collected in members of the ITT Population, comprised of participants that completed the observation period and Baseline visit, and were subsequently randomized to treatment and were administered at least one IV dose.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received placebo (0.9 percent sodium chloride) by intravenous (IV) infusion every 28 days for 18 months.</description>
        </group>
        <group group_id="E2">
          <title>GSK933776 (3 mg/kg)</title>
          <description>Participants received 3 milligram (mg)/kilogram (kg) GSK933776 by IV infusion every 28 days for 18 months.</description>
        </group>
        <group group_id="E3">
          <title>GSK933776 (6 mg/kg)</title>
          <description>Participants received 6 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
        </group>
        <group group_id="E4">
          <title>GSK933776 (15 mg/kg)</title>
          <description>Participants received 15 mg/kg GSK933776 by IV infusion every 28 days for 18 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Coronary ostial stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Subendocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Ventricular asystole</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Gallbladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Metastatic squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Toxic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Orthostatic hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Vitreous detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Macular fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

